Healthcare entity
Of the tracked stories, 2 of 2 also mention AbbVie, the most common co-covered peer. That works out to roughly 0.6 stories per week across a 22-day span. Source depth averages 2.5 original sources per story, versus 4.7 across the same-window beat baseline.
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention AbbVie, the most common co-covered peer. That works out to roughly 0.6 stories per week across a 22-day span. Source depth averages 2.5 original sources per story, versus 4.7 across the same-window beat baseline. Their average consequence score of 7 runs above the beat's 6.4 for that window. health-it accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. We currently track 2 Healthcare stories that mention Genmab, published between July 11, 2026 and August 1, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 179 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Genmab. Shared-story counts are live from our verified record — not editorial picks.
Clarification on US Primary Endpoint
Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
EHA 2026 Presentation
Additional study results presented at the European Hematology Association Congress.
Topline Results Announced
Genmab and AbbVie released initial data from the Phase 3 EPCORE DLBCL-1 trial.
For healthcare providers treating relapsed/refractory DLBCL, the failure of epcoritamab to improve overall survival in a Phase 3 confirmatory trial raises critical questions about its long-term benefit over chemoimmunotherapy, even though the drug is already available under accelerated approval.
A fixed-duration bispecific antibody plus lenalidomide dramatically improved progression-free survival over standard salvage chemoimmunotherapy in relapsed/refractory DLBCL, potentially offering healthcare systems a more effective and less toxic outpatient option while reshaping treatment guidelines and resource utilization.
Genmab is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
